Nanotechnology Now

Heifer International

Wikipedia Affiliate Button


Home > Press > Starpharma Holdings (ASX:SPL) Announce Commercial Product Launch Of Priostar(R) Dendrimer Technology As NanoJuiceTM

Starpharma Holdings Ltd (ASX:SPL, OTCQX:SPHRY) today announced the first commercial product launch based on its Priostar(R) dendrimer technology.

Starpharma Holdings (ASX:SPL) Announce Commercial Product Launch Of Priostar(R) Dendrimer Technology As NanoJuiceTM

Melbourne, Australia | Posted on April 21st, 2008

The product, a research reagent kit called NanoJuiceTM Transfection Kit for transporting DNA into cells, was developed under a license and supply agreement established in February 2007 between Starpharma's wholly owned US subsidiary Dendritic Nanotechnologies (DNT) and EMD Chemicals Inc., an affiliate of Merck KGaA, Darmstadt, Germany.

Under the commercial agreement, Starpharma retains full rights to all in vivo aspects of transfecting DNA and other nucleic acids such as siRNA with products based on Priostar(R) technology. Starpharma supplies the Priostar(R) dendrimers and will receive royalties from the sale of the transfection kits.

The NanoJuiceTM Transfection Kit launched by EMD Chemicals will be marketed to researchers as an improved product for optimal transfection efficiencies, low toxicity to cells and flexibility in the conditions of transfection.

In addition, the reagent is suitable for use with all types of cell growth media and does not require that the medium be changed after addition, thereby affording researchers substantial savings in time and money.

The transfection reagent in the kit is based on Starpharma's Priostar(R) dendrimers, highly branched spherical molecules with a high concentration of active groups on the surface that bind to DNA and are taken up by cells. It is the only reagent available that has been optimized for different cell lines through the use of different sizes of dendrimer.

The kit was designed to achieve efficient transfection of mammalian cells, especially those derived directly from tissues (so-called 'primary' cells), as well as the cell lines that are traditionally difficult to transfect.

The kit consists of Priostar(R) dendrimers mixed with microscopic lipid-based spheres that carry multiple positively charged groups.

DNT expects EMD to launch a related siRNA transfection reagent kit later in 2008.


About Starpharma Holdings Ltd
Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) is a world leader in the development of dendrimer nanotechnology for pharmaceutical, life-science and other applications. SPL is principally composed of two operating companies, Starpharma Pty Ltd in Melbourne, Australia and Dendritic Nanotechnologies, Inc in Michigan, USA. Products based on SPL's dendrimer technology are already on the market in the form of diagnostic elements and laboratory reagents.

The Company's lead pharmaceutical development product is VivaGel(R) (SPL7013 Gel), a vaginal microbicide designed to prevent the transmission of STIs, including HIV and genital herpes.

For more information, please click here

Dr Jackie Fairley
Chief Executive Officer
+61 3 8532 2704

Ben Rogers
Company Secretary
+61 3 8532 2702

Copyright © Business Wire 2008

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Strength in numbers: Researchers develop the first-ever quantum device that detects and corrects its own errors March 4th, 2015

New research could lead to more efficient electrical energy storage March 4th, 2015

Energy-generating cloth could replace batteries in wearable devices March 4th, 2015

Arrowhead to Present at 2015 Barclays Global Healthcare Conference March 4th, 2015


Toronto-based Environmental Technology Pioneer Green Earth Nano Science Expands in EU February 6th, 2015

DELSEY by Philippe Starck DELSEY Launches New Collection by Philippe Starck February 4th, 2015

NEI introduces NANOMYTE® SuperAi, a Durable Anti-ice Coating December 4th, 2014

Biosenta Inc. Updates New Household Disinfectant Testing Results; It Kills 100% of a Broad Range of Deadly Molds, Fungi, Bacteria, and Viruses, Including Ebola and Enterovirus D68 November 20th, 2014


Patent for the Novel Cancer Therapies – Ceramide Nanoliposomes March 4th, 2015

Arrowhead to Present at 2015 Barclays Global Healthcare Conference March 4th, 2015

Democratizing synthetic biology: New method makes research cheaper, faster, and more accessible March 3rd, 2015

Pens filled with high-tech inks for do-it-yourself sensors March 3rd, 2015


Experiment and theory unite at last in debate over microbial nanowires: New model and experiments settle debate over metallic-like conductivity of microbial nanowires in bacterium March 4th, 2015

Magnetic vortices in nanodisks reveal information: Researchers from Dresden and Jülich use microwaves to read out information from smallest storage devices March 4th, 2015

CiQUS researchers obtain high-quality perovskites over large areas by a chemical method March 4th, 2015

Arrowhead to Present at 2015 Barclays Global Healthcare Conference March 4th, 2015

The latest news from around the world, FREE

  Premium Products
Only the news you want to read!
 Learn More
University Technology Transfer & Patents
 Learn More
Full-service, expert consulting
 Learn More

Nanotechnology Now Featured Books


The Hunger Project

© Copyright 1999-2015 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE